Ideaya Biosciences: JPMorgan Sees 186% Price Potential and Puts the Biotech on its "Positive Catalyst Watch"
Reading Time: 3 minutes
Ideaya Biosciences (IDYA) positions itself as a biotechnology company specializing in precision oncology with a clear focus on developing targeted cancer therapies. The company pursues an approach of "synthetic lethality," aiming to specifically target cancer cells with particular genetic mutations. Leading programs and clinical progress Darovasertib (IDE196): Focused on Uveal Melanoma One of the leading candidates in Ideaya's pipeline is Darovasertib, a protein kinase C inhibitor being developed for the treatment of uveal melanoma (UM)....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
